Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer
2021-002449-13Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of indocyanine green in High-Grade Serous Ovarian Cancer (HGSOC), sponsored by UZ Leuven. Primary endpoint: Diagnostic accuracy of ICG fluorescence for peritoneal malignant lesions. Started Jul 2021; status: completed.
02
Drugs
indocyanine green
03
Conditions
High-Grade Serous Ovarian Cancer (HGSOC)
Beyond the preview
Go deeper on 2021-002449-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002449-13.